Navigation Links
Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
Date:1/14/2008

BRIDGEWATER, N.J. and CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were published this month in the January issue of the peer- reviewed journal Bone. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily, increases in lumbar spine bone mineral density (BMD) at one year were similar for patients taking either the monthly or daily dosing regimens. All patients were supplemented with calcium and vitamin D.

In the study, BMD was measured at the lumbar spine, total hip, femoral neck, and femoral trochanter. There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months at all sites. In the study, the tolerability and safety profiles also were generally similar for the monthly and daily dosing regimens of risedronate.

"Our goal is to provide patients with convenient dosing options for risedronate," said Nora Zorich, M.D., Ph.D., Vice President, Global R&D, P&G Pharmaceuticals. "If this dose regimen is approved, there will be a once monthly dose option available to patients seeking less frequent dosing of risedronate."

About the Study

The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) study is a 2-year, randomized, double-blind, active-control (5 mg daily risedronate) clinical trial which evaluated 1,292 postmenopausal women between 50 and 88 years old, mean age 64.9, from 47 clinical centers in 13 countries. The participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than -2.0 and at least one prevalent vertebral fracture. Patients were randomized to dosing regimens of either risedronate 150 mg monthly or risedronate 5 mg daily and received daily supplements of calcium
'/>"/>

SOURCE Procter & Gamble
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will increase to a value of over ... by expansion in the large direct energy device market. ... increasingly adopted due to the advantages they offer and ... findings from Decision Resources Group,s coverage of the U.S. ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana Therapeutics, ... biopharmaceutical company focused on the licensing, development and ... announced positive results from its pivotal field study ... treating pain in dogs with osteoarthritis.  In the ... assessment scores that were statistically significant compared to ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Development for Chronic Pain and Non-Pain ... Indications -, ... ) today announced that data from its multiple dose clinical,trial of tezampanel, ... the product candidate is safe and,well-tolerated in normal male and female subjects., ...
... Show PTC124 Addresses Underlying Cause of Genetic Disorders and ... Protein Function in Cystic Fibrosis Model, SOUTH PLAINFIELD, N.J., ... new preclinical data in the February 12,2008 edition of the ... PTC124, a novel drug designed to bypass nonsense mutations,was active ...
Cached Medicine Technology:Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 2Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 3Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated 4PTC Therapeutics Announces Publication of Preclinical Data in PNAS 2PTC Therapeutics Announces Publication of Preclinical Data in PNAS 3PTC Therapeutics Announces Publication of Preclinical Data in PNAS 4
(Date:12/22/2014)... Carlsbad, Ca (PRWEB) December 22, 2014 ... providing superior senior care service in San ... providing all members of its senior care team ... for caregivers from Golden Care is provided by ... seniors and professional caregivers with the most reliable ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... NC (PRWEB) December 22, 2014 ... the current Ebola virus epidemic are receiving ... U.S. government agencies, nongovernmental organizations (NGOs) and ... remains ongoing, healthcare workers, emergency responders, patients ... technologies such as the CmTP MediDefense ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... 2014 stronger than ever, having invested more than ... injured service members, veterans and their families. , ... for nearly a dozen nonprofits, helping with: veteran ... nursing scholarships; and life-coaches for severely injured veterans. ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
Breaking Medicine News(10 mins):Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2
... , , SOLON, Ohio, Aug. ... U.S. marketplace, Nestle USA is pleased to announce that NESTLE TOLL ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-a ) , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-b ) ... retail partners and consumers to identify the new batch of cookie ...
... home foreclosure epidemic may be taking its toll on ... of people studied while undergoing foreclosure reported depressive symptoms, ... according to new University of Pennsylvania School of Medicine ... Journal of Public Health. Many also reported an ...
... in the normal range appear to be associated with ... new study published online August 21 in the ... growth factors appear to be involved in the development ... levels and prostate cancer risk has been unclear. ...
... ... control a cell,s ability to adapt to changes in its environment, a finding that could ... , ... August 21, 2009 -- UCSF researchers have identified the two key circuits that control a ...
... , DALLAS, Aug. 21 Michael Ramsay, ... chief of the department of anesthesiology and pain management ... elected president of the International Liver Transplant Society (ILTS), ... international members specializing in hepatology, surgery, anesthesia, critical care, ...
... , , , , ... America, Inc., a leader in the home and office bottled water, filtration ... a three-year alliance with Susan G. Komen for the Cure(R), the world,s ... office bottled water brands, DS Waters will make a $30.00 donation to ...
Cached Medicine News:Health News:Updated With Photos: NESTLE(R) TOLL HOUSE(R) Re-launches With 'New Batch' Label 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 2Health News:More than 1/3 of homeowners in foreclosure suffer from major depression, Penn study shows 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 2Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 3Health News:UCSF Researchers Identify Two Key Pathways in Adaptive Response 4Health News:Dallas Physician Elected to Lead International Organ Transplant Society 2Health News:Dallas Physician Elected to Lead International Organ Transplant Society 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 2Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 3Health News:DS Waters of America, Inc. Partners With Susan G. Komen for the Cure(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: